Business plan: “Structure Biology-Contract Research

Organisation”

Our firm intends to be a collaborative, innovative provider of Gene-to-Structure products and services to the global life sciences and pharmaceutical industry,

striving to accelerate the process of Structure-Based Drug Discovery

(SBDD)”.

Corporation OverviewMission

• “Structures Private limited intends to be a collaborative, innovative provider of Gene-to-Structure products and services to the global life sciences and pharmaceutical industry, striving to accelerate the process of Structure-Based Drug Discovery”.

Vision

• To be among the top 10 companies in India to work for.• To acquire and maintain top 3 leadership position in our chosen area of

Business in India.• To consolidate our position of leadership in India in the area of

structural biology services to establish global presence.• Continuously create new opportunities for growth in our strategic

business and create added value for the customers.

Personal ProfileRAJIV TYAGI Gender; Male DOB: 23/02/1975 Citizenship (dual): Australia/India

EDUCATION

2002-2005, Ph.D. in Biochemistry/Protein crystallography University of Queensland (UQ), Brisbane, Australia

1998-1999, Master of BiotechnologyGriffith University, Brisbane, Australia

1994-1998, Bachelor of Microbiology (Hons.)

University of Delhi, Delhi, India PROFESSIONAL EXPERIENCE

Presently, Senior ScientistStructural Biology Division, Jubilant Biosys Limited , Bangalore, India

2006 - 2008,Postdoctoral Research AssociateBiology Department, Brookhaven National Laboratory, Upton, New York, USA

2005 - 2006, Research officer

Tumor Immunology Laboratory, Queensland Institute of Medical Research, Brisbane, Australia

2000 -2002, Research FellowCentre for Biotechnology, Birla Institute of Technology & Sciences (BITS), Rajasthan, India

Executive Summary• Our firm intends to be a collaborative, innovative provider of Gene-

to-Structure products and services to the global life sciences and pharmaceutical industry, striving to accelerate the process of Structure-Based Drug Discovery (SBDD)”.

• The aim of the company is to eventually have presence across the pharmaceuticals value chain of drug discovery services and contract research. The core competence of the company will be in Structure Based Drug Design. The Structural Biology Roadmap will be a strategic effort to create a "picture" gallery of the molecular shapes of proteins in the body. This research approach will involve the development of rapid, efficient, and dependable methods to produce protein samples that scientists can use to determine the three-dimensional structure, or shape, of a protein. The new effort will catalyze what is currently a hit-or-miss process into a organized, coordinated, systematic and streamlined routine, helping researchers clarify the role of protein shape in health and disease.

Executive Summary

• A limiting step in the determination of protein structures is the production of purified samples of the proteins in sufficient quantities for structural determination. Our company will forge a new chapter in bridging this limitation by scientific innovation to bring accelerated results. In addition continuously create new opportunities for growth in our strategic business and create added value.

• Structures require an investment partner for investment of INR 350 lakhs.

Challenges to Global Pharmaceutical• Late drug discovery- Even though the industry today uses cutting edge

technology to speed up the process of drug in market, there still are plenty of challenges. The companies are very critical of having new drugs to replace the existing top sellers. A new top selling drug can help the company maintain its lead in the segment.

• High cost and risk- The pharmaceutical is a high risk business and involves discovery process which is lengthy. It usually takes 12-15 years for a drug to come to market from initial compound identification. The cost for new drug in market could be between 1000-1200 million dollars. This has given big companies virtual monopoly in their own market.

• Structural Biology Points the Way to Important Medicines. Structure Based drug Design can shorten the time required for a new drug discovery as well as can reduce the overall cost.

• With more than 56,000 protein structures available in the Protein Data Bank (PDB), this number still represents less than 1% of the total number of protein sequences (over 7 million) cataloged in the current release of the UniProt protein knowledgebase (2009).

Challenges to Global Pharmaceutical

• If we are to have a better understanding of protein function and protein evolution, strategies are needed to ensure that the range of protein structures in the protein universe is more adequately covered.

• Until recent breakthroughs in knowledge of the human genome, almost all drugs targeted the same 500 proteins. With increased genomic information it has become known that approximately 10,000 proteins are therapeutically relevant potential drug targets. The world-wide demand by researchers for protein structures is growing rapidly. Structures is set up to determine increasing numbers of protein structures for pharmaceutical companies as this demand continues to grow.

Role of structure biology in SBDD

• In structure-based drug design, scientists marry computer modeling with protein structure data. The idea is to map every crevice of a protein target of a disease in order to design ways to stop the protein from working. An important component of the technique is

finding and/or tailor-making small molecules to "fit" the protein's shape. • The Structural Biology Roadmap will be a strategic effort to create a "picture" gallery of the

molecular shapes of proteins in the body. This research approach will involve the development of rapid, efficient, and dependable methods to produce protein samples that scientists can use to determine the three-dimensional structure, or shape, of a protein. The new effort will catalyze what is currently a hit-or-miss process into a organized, coordinated, systematic and streamlined routine, helping researchers clarify the role of protein shape in health and disease.

• A limiting step in the determination of protein structures is the production of purified samples of the proteins in sufficient quantities for structural determination. Our firm will forge a new chapter in bridging this limitation by scientific innovation to bring accelerated results. In addition continuously create new opportunities for growth in our strategic business and create added value.

Market

• The biotech industry in India crossed the $2-billion mark with exports surpassing the $1.2 billion mark, the industry registered nearly 31 percent growth in 2006-2007. In 2007-2008 it further grew 24%.

• There are two companies in India at the moment involved in the Gene to structure services.

• Other potential players / competitors in the future could be hardly one or two looking at the present scenario.

• The biggest entry barrier in Gene to structure services is the limited talent pool available in the field of Gene to structure Services (SBDD) worldwide, and in India and also the functional knowledge of SBDD process.

Service Offering

Our venture is planning to offer following broad range services• Crystal image annotation• Protein structure refinement• Gene to Structure services• Protein to structure services• Other structural biology related services

The aim of the company is to eventually have presence across the pharmaceuticals value chain of drug discovery services and custom research with core competency in Structure based drug design.

Strategy Business Model

• Type 1- FTE based arrangement- In this arrangement scientists will be dedicated for a particular customer and would not be used for any other work.

• Type 2- Project base arrangement- In this arrangement customer will make an initial payment as project initiation fee and pay the balance after the completion of project.

• Type 3- Milestone based payment- In this arrangement the payment will be based on the achievement of pre agreed milestones and success factors.

Investment Opportunity

• We require an investment partner for investment of a INR 350 lakh

• Looking for a investor, who can provide full or partial fund for starting up the business and then provide remaining fund in the second stage and third stage.

• We need funding for the start-up in three phases:

First = 50,00000 INR to set up infrastructure

Second= 20,00,0000 INR for instrumentation

Third = 50,00,000 as running costs.